SALARIUS PHARMACEUTICALS INC (SLRX) Stock Earnings & Estimates
USA - NASDAQ:SLRX - US79400X5032 - Common Stock
3.79 USD
-0.05 (-1.3%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.465M 313.45% | 5.233M 51.03% | 1.84M -64.84% | -100.00% | 12.113M | ||||
| EBITDA YoY % growth | -8.138M 60.27% | -7.768M 4.54% | -12.794M -64.69% | N/A -79.53% | N/A 43.90% | N/A 55.53% | N/A | N/A | |
| EBIT YoY % growth | -8.265M 60.09% | -7.786M 5.79% | -12.813M -64.55% | -22.734M -79.31% | -18.21M 43.87% | -6.242M 55.53% | -6.25M -8.99% | N/A | |
| Operating Margin | -238.52% | -148.79% | -696.28% | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -110.00 72.77% | -60.00 45.45% | -911.27 -44.00% | -5.25 93.92% | -4.12 21.55% | -9.35 -126.98% | -4.39 53.11% |
All data in USD
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -6.01 47.30% | -6.01 12.22% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -11.40 -119.23% | -36.72 | 25.32 | 68.95% |
| Q2 2024 Q2Q % growth | -377.90% | -54.67 | % | |
| Q1 2024 Q2Q % growth | -3.28 81.61% | -54.67 | 51.39 | 94.00% |
| Q4 2023 Q2Q % growth | 95.45% | -1.03 | % | |
| Q3 2023 Q2Q % growth | -5.20 73.68% | -9.79 | 4.59 | 46.90% |
| Q2 2023 Q2Q % growth | -11.44 36.44% | -10.58 | -0.86 | -8.12% |
| Q1 2023 Q2Q % growth | -17.84 31.38% | -20.40 | 2.56 | 12.55% |
| Q4 2022 Q2Q % growth | -22.64 -25.78% | -17.58 | -5.06 | -28.75% |
| Q3 2022 Q2Q % growth | -19.76 -23.50% | -20.81 | 1.05 | 5.04% |
| Q2 2022 Q2Q % growth | -18.00 -28.57% | -21.42 | 3.42 | 15.97% |
| Q1 2022 Q2Q % growth | -26.00 -116.67% | -18.36 | -7.64 | -41.61% |
| Q4 2021 Q2Q % growth | -18.00 10.00% | -17.34 | -0.66 | -3.81% |
| Q3 2021 Q2Q % growth | -16.00 20.00% | -13.26 | -2.74 | -20.66% |
| Q2 2021 Q2Q % growth | -14.00 46.15% | -11.56 | -2.44 | -21.10% |
| Q1 2021 Q2Q % growth | -12.00 72.73% | -11.22 | -0.78 | -6.95% |
| Q4 2020 Q2Q % growth | -20.00 | -22.44 | 2.44 | 10.87% |
| Q3 2020 Q2Q % growth | -20.00 | -21.42 | 1.42 | 6.63% |
| Q2 2020 Q2Q % growth | -26.00 | -33.66 | 7.66 | 22.76% |
| Q1 2020 Q2Q % growth | -44.00 | -89.76 | 45.76 | 50.98% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2022 Q2Q % growth | -100.00% | % | ||
| Q1 2022 Q2Q % growth | -100.00% | % | ||
| Q4 2021 Q2Q % growth | -100.00% | 441.997K | -441.997K | -100.00% |
| Q3 2021 Q2Q % growth | -100.00% | 1.182M | -1.182M | -100.00% |
| Q2 2021 Q2Q % growth | 571.4K -54.04% | 1.305M | -733.6K | -56.21% |
| Q1 2021 Q2Q % growth | 1.269M 12.01% | 1.397M | -128.2K | -9.18% |
| Q4 2020 Q2Q % growth | 1.479M 42.38% | 1.507M | -28.1K | -1.86% |
| Q3 2020 Q2Q % growth | 1.378M 57.51% | 1.37M | 8.2K | 0.60% |
| Q2 2020 Q2Q % growth | 1.243M 38.79% | 1.217M | 26.3K | 2.16% |
| Q1 2020 Q2Q % growth | 1.133M 72.79% | 1.414M | -281.2K | -19.89% |
| Q4 2019 Q2Q % growth | 1.039M | 3.37M | -2.331M | -69.18% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 0% |
| Revenue | N/A | N/A | N/A | N/A |